Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 11 | 2025 | 261 | 2.590 |
Why?
|
| Neuromyelitis Optica | 8 | 2023 | 24 | 2.490 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 6 | 2025 | 65 | 2.420 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2025 | 608 | 1.290 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2025 | 3479 | 0.950 |
Why?
|
| Immunologic Factors | 4 | 2020 | 176 | 0.900 |
Why?
|
| Feasibility Studies | 1 | 2024 | 758 | 0.710 |
Why?
|
| Premedication | 1 | 2018 | 57 | 0.570 |
Why?
|
| Interferon Type I | 2 | 2011 | 164 | 0.530 |
Why?
|
| Immunosuppressive Agents | 4 | 2023 | 990 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 1002 | 0.430 |
Why?
|
| Fenfluramine | 3 | 1999 | 20 | 0.420 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2014 | 3 | 0.410 |
Why?
|
| Rituximab | 3 | 2023 | 128 | 0.390 |
Why?
|
| Hemianopsia | 1 | 2012 | 4 | 0.370 |
Why?
|
| Optic Nerve | 1 | 2012 | 35 | 0.360 |
Why?
|
| Natalizumab | 3 | 2018 | 21 | 0.350 |
Why?
|
| Retinal Ganglion Cells | 1 | 2012 | 71 | 0.350 |
Why?
|
| Visual Pathways | 1 | 2012 | 152 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 78 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-fos | 4 | 2001 | 66 | 0.310 |
Why?
|
| Optic Neuritis | 1 | 2009 | 10 | 0.310 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 234 | 0.290 |
Why?
|
| Alemtuzumab | 2 | 2020 | 90 | 0.290 |
Why?
|
| Aquaporin 4 | 2 | 2023 | 9 | 0.290 |
Why?
|
| Adult | 14 | 2025 | 27955 | 0.280 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 8 | 0.280 |
Why?
|
| Salivary Glands, Minor | 1 | 2008 | 9 | 0.280 |
Why?
|
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.280 |
Why?
|
| Serotonin Agents | 2 | 1999 | 13 | 0.280 |
Why?
|
| Disability Evaluation | 2 | 2025 | 171 | 0.250 |
Why?
|
| Tomography, Optical Coherence | 3 | 2017 | 131 | 0.240 |
Why?
|
| Female | 17 | 2025 | 48779 | 0.240 |
Why?
|
| Humans | 24 | 2025 | 93615 | 0.240 |
Why?
|
| Middle Aged | 10 | 2025 | 27621 | 0.230 |
Why?
|
| Male | 16 | 2025 | 44578 | 0.220 |
Why?
|
| Brain | 4 | 2025 | 2375 | 0.220 |
Why?
|
| Recurrence | 2 | 2023 | 1191 | 0.190 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 85 | 0.190 |
Why?
|
| Azathioprine | 1 | 2023 | 122 | 0.190 |
Why?
|
| Inflammation | 1 | 2008 | 1049 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1546 | 0.170 |
Why?
|
| White Matter | 2 | 2018 | 97 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2024 | 629 | 0.160 |
Why?
|
| Case-Control Studies | 1 | 2024 | 1933 | 0.150 |
Why?
|
| Hypothalamus | 2 | 2001 | 80 | 0.150 |
Why?
|
| Serotonin Antagonists | 2 | 2001 | 24 | 0.150 |
Why?
|
| Ranitidine | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cetirizine | 1 | 2018 | 12 | 0.140 |
Why?
|
| Diphenhydramine | 1 | 2018 | 14 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 63 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 66 | 0.140 |
Why?
|
| Gray Matter | 1 | 2018 | 44 | 0.140 |
Why?
|
| Neurotransmitter Agents | 1 | 1999 | 102 | 0.140 |
Why?
|
| Amygdala | 1 | 1999 | 86 | 0.140 |
Why?
|
| Acetaminophen | 1 | 2018 | 61 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2020 | 454 | 0.140 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2018 | 5 | 0.140 |
Why?
|
| Limbic Encephalitis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Glutamate Decarboxylase | 1 | 2018 | 34 | 0.140 |
Why?
|
| Fenclonine | 1 | 1997 | 2 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 1997 | 11 | 0.130 |
Why?
|
| Serotonin | 1 | 1999 | 209 | 0.130 |
Why?
|
| Encephalitis | 1 | 2018 | 46 | 0.130 |
Why?
|
| Age Factors | 2 | 2020 | 1907 | 0.130 |
Why?
|
| Fluoxetine | 1 | 1997 | 41 | 0.130 |
Why?
|
| Prosencephalon | 1 | 1997 | 68 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2023 | 10186 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 701 | 0.130 |
Why?
|
| Brain Stem | 1 | 1997 | 163 | 0.130 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2018 | 142 | 0.120 |
Why?
|
| Antibodies | 1 | 2018 | 347 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 353 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2018 | 9108 | 0.120 |
Why?
|
| Retina | 1 | 2017 | 214 | 0.120 |
Why?
|
| Sex Factors | 1 | 2018 | 1104 | 0.110 |
Why?
|
| Disease Progression | 2 | 2018 | 1531 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 501 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2018 | 812 | 0.110 |
Why?
|
| Epilepsy | 1 | 2018 | 434 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2001 | 1243 | 0.090 |
Why?
|
| Aquaporins | 1 | 2012 | 14 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2018 | 277 | 0.090 |
Why?
|
| Visual Field Tests | 1 | 2012 | 15 | 0.090 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 464 | 0.090 |
Why?
|
| Neurons | 2 | 2001 | 1575 | 0.090 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 179 | 0.080 |
Why?
|
| Prevalence | 2 | 2020 | 1322 | 0.080 |
Why?
|
| Glatiramer Acetate | 1 | 2009 | 14 | 0.080 |
Why?
|
| Receptors, Serotonin | 2 | 2001 | 34 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 2009 | 65 | 0.080 |
Why?
|
| Adolescent | 3 | 2017 | 9610 | 0.080 |
Why?
|
| Thalamus | 2 | 2022 | 132 | 0.070 |
Why?
|
| Young Adult | 2 | 2018 | 6938 | 0.070 |
Why?
|
| Rats | 4 | 2001 | 4042 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2011 | 729 | 0.070 |
Why?
|
| Interferon-beta | 1 | 2009 | 127 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 982 | 0.070 |
Why?
|
| Sjogren's Syndrome | 1 | 2008 | 34 | 0.070 |
Why?
|
| Organ Size | 2 | 2018 | 361 | 0.070 |
Why?
|
| Animals | 6 | 2014 | 28041 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 1389 | 0.060 |
Why?
|
| Peptides | 1 | 2009 | 654 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3835 | 0.060 |
Why?
|
| Biomarkers | 1 | 2011 | 1912 | 0.050 |
Why?
|
| Biopsy | 1 | 2008 | 1177 | 0.050 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2001 | 40 | 0.050 |
Why?
|
| Limbic System | 1 | 2022 | 25 | 0.050 |
Why?
|
| Oxytocin | 2 | 2001 | 75 | 0.040 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2001 | 7 | 0.040 |
Why?
|
| Corticosterone | 1 | 2001 | 35 | 0.040 |
Why?
|
| Renin | 1 | 2001 | 67 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2001 | 114 | 0.040 |
Why?
|
| Vitamin D | 1 | 2023 | 272 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4565 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2020 | 224 | 0.040 |
Why?
|
| Child | 1 | 2010 | 7359 | 0.040 |
Why?
|
| Enkephalins | 1 | 1999 | 14 | 0.040 |
Why?
|
| Neurotensin | 1 | 1999 | 10 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2018 | 58 | 0.040 |
Why?
|
| Ritanserin | 1 | 1998 | 1 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 287 | 0.030 |
Why?
|
| Atrophy | 1 | 2018 | 128 | 0.030 |
Why?
|
| Carboxy-Lyases | 1 | 2018 | 18 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 102 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 68 | 0.030 |
Why?
|
| Gyrus Cinguli | 1 | 1997 | 50 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2018 | 293 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1997 | 126 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2018 | 188 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1007 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 454 | 0.030 |
Why?
|
| Personality | 1 | 2018 | 140 | 0.030 |
Why?
|
| Piperazines | 1 | 1998 | 284 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2017 | 217 | 0.030 |
Why?
|
| Pyridines | 1 | 1998 | 302 | 0.030 |
Why?
|
| Seizures | 1 | 2018 | 311 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 938 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 875 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1165 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 917 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2543 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1275 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2012 | 43 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2012 | 110 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1866 | 0.020 |
Why?
|
| Rabbits | 1 | 2012 | 613 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2012 | 696 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 5406 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5912 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1954 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 1993 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 2889 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7645 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2828 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 759 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 20469 | 0.010 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2001 | 2 | 0.010 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2001 | 14 | 0.010 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2001 | 13 | 0.010 |
Why?
|
| Prolactin | 1 | 2001 | 89 | 0.010 |
Why?
|
| Fluorobenzenes | 1 | 2001 | 34 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2001 | 124 | 0.010 |
Why?
|
| Piperidines | 1 | 2001 | 165 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 12233 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1913 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1790 | 0.010 |
Why?
|